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Abstract
Background: Deletion of the Williams-Beuren syndrome (WBS) critical region (WBSCR), at 7q11.23, causes a
developmental disorder commonly characterized by hypersociability and excessive talkativeness and often
considered the opposite behavioral phenotype to autism. Duplication of the WBSCR leads to severe delay in
expressive language. Gene–dosage effects on language development at 7q11.23 have been hypothesized.
Methods: Molecular characterization of the WBSCR was performed by fluorescence in situ hybridization and
high-resolution single-nucleotide polymorphism array in two individuals with severe autism enrolled in a genetic
study of autism who showed typical WBS facial dysmorphism on systematic clinical genetic examination. The
serotonin transporter promoter polymorphism (5-HTTLPR, locus SLC6A4) was genotyped. Platelet serotonin levels
and urinary 6-sulfatoxymelatonin excretion were measured. Behavioral and cognitive phenotypes were examined.
Results: The two patients had common WBSCR deletions between proximal and medial low copy repeat
clusters, met diagnostic criteria for autism and displayed severe impairment in communication, including a total
absence of expressive speech. Both patients carried the 5-HTTLPR ss genotype and exhibited platelet
hyperserotonemia and low melatonin production.
Conclusions: Our observations indicate that behaviors and neurochemical phenotypes typically associated with
autism can occur in patients with common WBSCR deletions. The results raise intriguing questions about
phenotypic heterogeneity in WBS and regarding genetic and/or environmental factors interacting with specific
genes at 7q11.23 sensitive to dosage alterations that can influence the development of social communication
skills. Thus, the influence of WBSCR genes on social communication expression might be dramatically modified
by other genes, such as 5-HTTLPR, known to influence the severity of social communication impairments in
autism, or by environmental factors, such as hyperserotonemia, given that hyperserotonemia is found in WBS
associated with autism but not in WBS without autism. In this regard, WBS provides a potentially fruitful model
with which to develop integrated genetic, cognitive, behavioral and neurochemical approaches to study
genotype–phenotype correlations, possible gene–environment interactions and genetic background effects. The
results underscore the importance of considering careful clinical and molecular genetic examination of
individuals diagnosed with autism.
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Background
Williams-Beuren syndrome (WBS) is a developmental
disorder caused by a hemizygous recurrent deletion of
the WBS critical region (WBSCR) at chromosomal band
7q11.23, which includes ELN (gene coding for elastin)
and 27 additional coding genes [1]. The common deletion
results from recombination between misaligned low copy
repeat (LCR) sequences flanking the critical region. Three
LCR clusters have been delineated: centromeric, medial
and telomeric. Each LCR cluster is broken down in highly
homologous subregions (blocks A, B and C). The dele-
tions arise as a consequence of a nonallelic homologous
recombination. The deletion occurs between proximal
and medial LCRs in about 95% of WBS cases, and it
occurs between proximal and distal LCRs in the remaining
cases. The size of the deletion is approximately 1.55 Mb
for the small deletion and approximately 1.84 Mb for
the larger one [1-5]. However, the precise size depends
upon the exact position of the breakpoints in each block.
The physical WBS phenotype includes typical facial
dysmorphism (elfin-like face), vascular stenoses (most com-
monly aortic stenosis), infantile hypercalcemia, dental
problems, kidney abnormalities, feeding and sleep dis-
turbances, abnormal gait and developmental delay with
short stature [6,7]. The characteristic cognitive and be-
havioral profile includes some strengths in socialization
(overfriendliness and enhanced social interest) and commu-
nication (excessive talkativeness and hyperverbal speech)
with relatively good short-term verbal memory, contrasting
with a common mild to moderate intellectual disability
(it is noteworthy that some patients with WBS have been
reported to show severe intellectual disability [8]) and se-
vere impairment in visuospatial abilities associated with
hyperacusis, peer interaction difficulties, general anxiety
and behavioral problems such as hyperactivity [9-13].
The roles played by most genes deleted in the WBSCR
are largely unknown. However, deletion of the elastin
gene (ELN) is clearly involved in the vascular anomalies
[14], and the LIMK1, GTF2I and GTFIIRD1 genes have
been implicated in cognitive developmental delay and
visuospatial deficiency [3,7,15]. Recently, duplication of
the WBSCR has been reported to be associated with in-
tellectual disability, severe delay in expressive language
and autism spectrum disorders, suggesting that specific
genes within WBSCR can influence language and social
development through genedosage effects [16-19].
Here we report on two unrelated Caucasian individuals
with typical WBSCR deletion and severe autistic disorder,
including a total absence of expressive language, found
during a systematic clinical genetic examination of a co-
hort of 71 individuals with autistic disorder enrolled for
a genetic study of autism. The existence of such individuals
raises questions about the common idea that WBS
(regarding its characteristics of overfriendliness and
excessive talkativeness) represents the opposite pheno-
type of autism (a developmental disorder characterized
by social and communication deficits and stereotypies)
and suggests that genetic background or epistatic effects
can markedly influence the effects of WBSCR deletion on
the development of social communication skills. To study
further the characteristics of these two individuals, be-
havioral and cognitive phenotypes were examined by
assessing severity of impairments in the main behavioral
domains of autistic disorder and in cognitive function-
ing. Genetic analyses were performed by the molecular
characterization of the WBSCR and by genotyping the
serotonin transporter promoter polymorphism (5-HTTLPR
at 17q11.2, locus SLC6A4). Given the well-replicated hyper-
serotonemia of autism [20,21] and multiple reports [22,23]
of decreased melatonin production in autism (melatonin
is a pineal neurohormone directly synthesized from sero-
tonin), neurochemical phenotype was assessed by measur-
ing whole-blood serotonin and urinary excretion of the
melatonin metabolite 6-sulfatoxymelatonin. As these two
neurochemical measures are the most well-established
autism biomarkers (albeit without sufficient sensitivity
or specificity to be used alone in assessing autism risk),
their measurement was included in the characterization
of the WBS individuals under study.
Methods
Patients and clinical genetic examination
On the basis of direct clinical observation of the two
patients by two independent child psychiatrists, the
diagnosis of autistic disorder was made according to the
criteria set forth in the Diagnostic Manual of Mental
Disorders, Fourth Edition–Text Revision (DSM-IV-TR)
[24], and the International Classification of Diseases, 10th
Revision (ICD-10) [25]. The protocol was approved by
the ethics committee of Bicêtre Hospital (CPP of Bicêtre).
Written informed consent was obtained from the partici-
pants parents and guardians, including a written consent
to publish. The clinical characteristics and physical fea-
tures of both patients are presented in Table 1.
Patient 1, a 17.6-year-old male, was born prematurely
at 32 weeks of gestation. The pregnancy was complicated
by maternal depression. Patient 1 had feeding difficulties
in infancy related to a gastroesophageal reflux. According
to parental report, sleep disturbances were present since
the first year of life and included longer sleep latency as-
sociated with body rocking in the bed before sleeping
and very deep sleep. The current presence of these distur-
bances was confirmed by Actiwatch monitoring (Mini
Mitter Co, Bend, OR, USA). The patient first walked at
3.5 years old with balance disturbances, never developed
expressive language and was not toilet-trained (no blad-
der or bowel control). The parents and the pediatrician
noticed autistic behaviors during the first months of life,
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such as absence of eye contact and absence of facial ex-
pressions directed toward others. Referral to a child-
care center for autistic disorder occurred at 3.5 years of
age. On the basis of dysmorphic facial features (large
forehead, broad nose and long philtrum, dental malocclu-
sion) and mild pulmonary stenosis, a clinical diagnosis
of WBS was initially suggested in infancy, but cytoge-
netically confirmed only during our systematic genetic
survey 15 years later.
Patient 2, a 19.2-year-old male, was born after a full-
term pregnancy with no neonatal complications. On the
basis of parental report, sleep disturbances were present
since infancy and included nocturnal and early morning
awakenings (current presence confirmed by Actiwatch
monitoring). The patient first walked at 17 months but
kept an unsteady gait. He never developed expressive
language, and sphincter control was acquired only be-
tween ages 12 and 15 years (daytime bladder and bowel
control at 12 years, nighttime bladder control at 15 years).
Autistic behaviors, such as absence of social smile and
vocalization directed toward others, were noticed by the
parents during the first year of life and reported by the
pediatrician shortly before 3 years of age. The mother kept
him at home until he was referred to a child-care center
for autistic disorder at the age of 5. As with patient 1, a
diagnosis of WBS was made only during our systematic
genetic survey involving a clinical genetic examination.
The clinical genetic examination showed growth retard-
ation for both patients (see Table 1 for birth and current
height, weight and head circumference). Cardiac exam-
ination, including echocardiography, revealed mild pul-
monic valve stenosis in patient 1 and was negative for
patient 2. Dysmorphic features were observed in patient
1, including dental malocclusion and typical WBS facial
dysmorphism (hypertelorism, short nose with anteverted
nostrils, thick lips with everted lower lip and sagging
cheeks). Patient 2 had also the characteristic facial features
of WBS (elfin-like face). For both patients, the neurological
examination showed balance disturbances and an abnormal
gait (Table 1). In addition, brisk reflexes were observed for
patient 2.
Behavioral and cognitive assessments
Diagnostic and behavioral assessments were performed
using the Autism Diagnostic InterviewRevised (ADIR)
and the Autism Diagnostic Observation Schedule (ADOS)
scales [26] (Table 2).
Table 1 Demographic information, physical features and medical informationa
Characteristics Patient 1 Patient 2
Demographics
Sex M M
Age (yr; mo) 17;6 19;2
Age autistic disorder reported by a professional (yr; mo) 0;11 2;11
Age at referral to an autism center (yr; mo) 3;6 5;9
Age at WBS diagnosis (yr; mo) 17;6 19;2
Clinical genetic examination and physical features
Birth height 45 cm 48 cm
Birth weight 1,680 g 3,080 g
Birth head circumference 30 cm 33.5 cm
Current height 160 cm 161 cm
Current weight 44.2 kg 47 kg
Current head circumference 50 cm 53 cm
Heart defectb Mild PS None
Infantile hypercalcemia No No
Kidney abnormalities None None
Developmental anomalies Bilateral inguinal hernia and ectopic testis Bilateral inguinal hernia and cutaneous cysts
Facial dysmorphism Typical WBS features Typical WBS features
Walkingc Unstable Unstable
Neurological examination Unremarkable Brisk reflexes
a
PS pulmonary stenosis, WBS Williams-Beuren syndrome. bFor patient 1, a heart murmur was detected at 3 weeks old, and the diagnosis of mild PS was made by
cardiologists; for patient 2, a systolic heart murmur was detected at 1 year old, but there was no heart defect. cPatient 1 had an abnormal gait, needed assistance
to maintain balance when standing upright and required hand-holding when walking uphill or downhill; patient 2 also had balance disturbances and an
abnormal gait (head forward and bent back like his father and brother).
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The ADIR is an extensive semistructured parental
interview, and the ADOS involves direct observation of
the patient through a standardized semistructured situation
of games. The ADIR and the ADOS were administered by
two trained psychiatrists certified in the administration
of these scales. The ADIR and ADOS scales were used
to assess the three major domains of autistic impair-
ment: reciprocal social interactions, verbal and nonver-
bal communication, stereotyped behaviors and restricted
interests. We used ADOS module 1, which is dedicated to
individuals with no or limited speech. The severity of im-
pairment in the major domains and subdomains of autism
were scored using the subset items included in the ADIR
and ADOS algorithms. The ADIR and ADOS items are
scored on an ordinal scale from 1 to 3 according to autism
severity, with 0 coding meaning that the autistic behavior
was not present. Interjudge reliability with respect to the
critical distinction between mild, moderate and severe
impairment was excellent, with an interjudge agreement
of 94% between the two expert raters. The ADIR scale
is validated to assess the behavior that was most abnor-
mal during the 4- to 5-year-old period and the current
behavior. The ADIR algorithm is based on the 4- to
5-year-old period of life. We also reported the ratings
of the subset of ADIR items included in the ADIR
algorithm for the current period to see the evolution
between these two periods of life (Table 3). In addition,
the ADIR and the ADOS were coded independently, but
the ratings reported in Table 3 for the current period took
into consideration the actual direct observation of the
patient during the ADOS administration when a compe-
tency was observed. This approach, combining multiple
sources based on the clinicians judgment and the
administration of the ADIR completed by the ADOS,
is recommended [27] and improves the confidence one
can have in the current period assessment.
Cognitive functioning was assessed by a psychologist
using the age-appropriate Wechsler Adult Intelligence
Scale III (WAIS-III) [28] and the Kaufman Assessment
Battery for Children (K-ABC) [29], given the interest of the
K-ABC in nonverbal individuals, especially in language-
disordered children.
Molecular analyses: single-nucleotide polymorphism array
and SLC6A4 genotyping
DNA was isolated from peripheral blood lymphocytes by
following standard procedures. We excluded atypical re-
arrangement by single-nucleotide polymorphism (SNP)
array genotyping. For patient 1, a whole-genome SNP
array was performed using Illumina HumanCytoSNP-12
v1.0 DNA Analysis BeadChip Kit (Illumina, San Diego,
CA, USA) and analyzed using Illumina GenomeStudio
software (Genotyping 1.1.9, Genome Viewer 1.1.11) with
copy number variation (CNV Partition 2.3.4) according to
the manufacturers recommendations. The reference used
was genome build 36.1. For patient 2, a whole-genome
SNP array was performed using Illumina HumanCNV370-
Quad v3.0 software and analyzed using IlluminaBeadStudio
Table 2 Autistic impairments and neurobehavioral characteristics
Characteristics Patient 1 Patient 2
Autistic behavioral domains and autism diagnosisa
ADI–R
Abnormalities of development evident at or before age 36 months
(cutoff = 1)
5 4
Nonverbal communication (cutoff = 7) 14 12
Reciprocal social interaction (cutoff = 10) 26 23
Repetitive behaviors and stereotyped patterns (cutoff = 3) 9 9
ADOS (module 1)
Communication (cutoff = 4) 5 5
Reciprocal social interaction (cutoff = 7) 13 8
Communication + social interaction total (cutoff = 12) 18 13
Play 3 1
Repetitive behaviors and stereotyped patterns 5 4
Expressive behaviors
Verbal language None (total absence of words) None (total absence of words)
Self-injurious behaviors Ear-slapping, hand-biting Self-scratching until bleeding,
elbow-banging
aAccording to the ADI–R (parental interview) or the ADOS (direct observation of the patient) algorithm, the DSM-IV-TR and the ICD-10 diagnostic criteria for
autistic disorder are fulfilled when the total scores of each domain reach the cutoff point.
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v2009. The reference used was genome build 36, according
to the manufacturers recommended protocol. Slightly dif-
ferent whole-genome SNP array procedures were used due
to the laboratorys change to the new protocol.
In addition, genotyping with respect to the promoter
polymorphism (serotonin transporterlinked polymorphic
region, 5-HTTLPR) of the serotonin transporter gene
locus SLC6A4 (solute carrier family 6 (neurotransmitter
transporter, serotonin), member 4) was performed
using the polymerase chain reaction (PCR) primers 5-
ATGCCAGCACCTAACCCCTAATGT-3 (position −1,400
to −1,377) and 5-GGACCGCAAGGTGGGCGGGA-3
(position −1,001 to −982). These primers gave two products
after PCR amplification, a short variant (s) of 375 bp
and a long variant (l) of 419 bp. Analysis followed stand-
ard protocol.
Determination of blood serotonin and urinary
6-sulfatoxymelatonin
Levels of platelet serotonin were determined in whole
blood by high-performance liquid chromatography according
to a previously described method with a day-to-day co-
efficient of variation of 5.9% [30]. Secretion of melatonin,
a pineal gland hormone produced from serotonin, was
assessed by measuring the overnight urinary output of the
predominant melatonin metabolite, 6-sulfatoxymelatonin
(6-SM). It is well-established that urinary excretion of
6-SM gives an accurate reflection of pineal melatonin
secretion [31]. Nocturnal urine was collected at home
by caregivers during a 12-h period (from 8 PM to 8 AM).
Collected urine samples were stored in a refrigerator
until delivered to the laboratory within 24 h of collec-
tion. The volume of the urine collection was measured,
and a portion was frozen until analyzed for 6-SM. Blinded
analysis of urine 6-SM levels was performed by radio-
immunoassay using an assay kit from Stockgrand Ltd
(Guildford, UK). The urine samples were diluted prior
to assay (1:250). The intra-assay coefficient of variation
was 6% for a 0.030 μg/ml control sample value. Excre-
tion of 6-SM was expressed as micrograms excreted per
hour over the collection period. The urinary 6-SM con-
centration (μg/ml) was multiplied by the collection volume
in milliliters and divided by the 12 hours of collection.
Results
Characterization of the deletion by single-nucleotide
polymorphism array
The molecular characterization by fluorescence in situ
hybridization indicated that the elastin gene was deleted
in both patients. The deletion was further characterized
by high-density SNP array. The results are presented in
Table 4. Both patients had the common short deletion,
with recombination occurring between proximal and med-
ial clusters. For patient 1, the deletion spanned 1.41 Mb.
For patient 2, the deletion spanned 1.67 Mb. No other
additional copy number variation was detected, and no
isodisomic segment was identified using a 1-Mb window.
Table 3 Assessment of the autistic behavioral domains and subdomains based on the Autism Diagnostic
Interview–Revised algorithma
Assessment Patient 1 Patient 2
Ages 4 to 5 years Age 17 years Ages 4 to 5 years Age 19 years
Total social interaction 2 1 2 1
B1: Failure to use nonverbal behaviors to regulate social interaction 2 1 2 1
B2: Failure to develop peer relationships 2 1 3 1
B3: Lack of shared enjoyment 3 2 3 1
B4: Lack of socioemotional reciprocity 2 1 2 1
Total nonverbal communication 3 2 3 1
C1: Delayed spoken language and failure to compensate through gesture 2 2 2 1
C4: Lack of varied spontaneous make-believe or social imitative play 3 1 3 0
Total repetitive behaviors and stereotyped patterns 3 2 2 2
D1: Encompassing preoccupation or circumscribed pattern of interestb 3 2 2 2
D2: Compulsive adherence to nonfunctional routines or rituals 1 1 2 0
D3: Stereotyped and repetitive motor mannerismsc 3 2 3 3
D4: Preoccupations with part of objects or nonfunctional elements 2 1 1 2
aThe scoring has been transformed in median values as previously described [45] (0: autistic behavior is not present, 1: mild impairment, 2: moderate impairment,
and 3: severe impairment). bPatient 1 showed unusual repetitive sensory interests, such as fascination for spinning objects and water in the shower, sniffing
people, actively seeking “wind sensations” (manual or electric fan) and interest in musical objects with hyperresponsivity to auditory stimuli. Patient 2 showed
unusual repetitive sensory interests, such as fascination with spinning objects and water in the bath, sniffing people and interest in musical objects with
hyperacusis to loud sounds. (He covered his ears at screams, babies crying and sounds of an airplane). cPatient 1 showed finger mannerisms and head-rocking,
and patient 2 showed hand-flapping and toe-walking.
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HTT allele genotyping
Genotyping with respect to the polymorphism of the
promoter of the serotonin transporter gene (5-HTTLPR,
locus SLC6A4) showed that both patients bore the ss
genotype.
Behavioral and cognitive phenotypes
The diagnosis of autism based on the experienced clini-
cians judgment was confirmed by the ADIR and ADOS
ratings. Indeed, the two patients fulfilled DSM-IV-TR and
ICD-10 diagnostic criteria for autistic disorder based on
the ADIR (4- to 5-year-old period) and ADOS (current
period) algorithms [26] (see Table 4 for patient informa-
tion). As shown in Table 3, both patients displayed severe
impairment in communication, including a total absence
of expressive speech in social interaction (with a positive
evolution after the age of 6 years, based on the ADIR
parental interview), and stereotyped behaviors or interests,
such as fascination with spinning objects. Autistic behav-
ior was reported for both patients in the first year of life
by their parents, and both patients were diagnosed be-
fore the age of 3 years with autistic disorder according
to Kanners criteria [32] and based on a professionals
judgment.
Both patients showed severe intellectual disability. Their
verbal IQ scores showed a floor effect (that is, the lowest
scores on the norms) related to the total absence of verbal
language. Their performance and full-scale IQ scores
also showed a floor effect on the WAIS-III scale (verbal
IQ = 46, performance IQ = 45, full-scale IQ = 40). On
the K-ABC scale, patient 1 had a raw score of 5 on the
Triangle subtest (corresponding to the performance of
a 4.5-year-old child) but failed the other nonverbal sub-
tests. Patient 2 was able to complete all the nonverbal
subtests and obtained a raw score of 10 on the Triangle
subtest. On the basis of his performance on the non-
verbal scale, patient 2s performance corresponded to
that of a 5-year-old child.
Serotonin and 6-sulfatoxymelatonin measures
Patients 1 and 2 were both markedly hyperserotonemic with
whole-blood serotonin levels of 440 ng/ml and 370 ng/ml,
respectively (mean ± SD value in healthy controls: 152 ±
50 ng/ml) [21]. In addition, both patients exhibited sub-
stantially reduced nocturnal urinary 6-SM excretion rates
(patients 1 and 2: 0.57 μg/h and 0.64 μg/h, respectively)
compared to healthy controls (mean value ± SD: 1.80 ±
1.59 μg/h) [22].
Discussion
Herein we report on two males originally recruited to
participate in a genetic study of autism who were discov-
ered, upon clinical and molecular examination, to have
classic WBSCR deletions. Although both individuals had
the typical WBS facies and exhibited sleep problems often
seen in WBS patients, their behavioral phenotype stood in
contrast to that typical of people with WBS. Quite unlike
the common WBS profile of talkativeness, overfriendliness
and mild to moderate intellectual disability, both patients
displayed severe impairments in verbal communication
and social interaction, together with severe intellectual dis-
ability, and, more specifically, met the criteria for autism. In
addition, both patients exhibited platelet hyperserotonemia
and low nocturnal urinary melatonin excretion, neuro-
chemical phenotypes associated with autism [20,22,23,33].
Thus, behavioral and neurochemical phenotypes typically
associated with autism were observed in these two pa-
tients with WBS.
The presence of autistic behavioral and neurochemical
phenotypes in WBS patients could be due to the co-
occurrence in these individuals of the WBSCR deletion
with other genetic and/or environmental risk factors
for autism, or it could reflect an alternate expression of
WBS. Only 13 patients have previously been reported in
four countries other than France (six in the United States,
four in Sweden, two in Germany and one in Turkey) to
have the common WBSCR deletion while also meeting
Table 4 Characterization of the Williams-Beuren syndrome critical region deletion by single-nucleotide
polymorphism arraya
Characteristics Patient 1 Patient 2
Size of the deletion (Mb) 1.41 1.67
Centromeric breakpoint (SNP nt position)
First hemizygous probe locus 72360917 72229683
Homology block in centromeric LCR C B
Effect Intronic interruption of the FKBP6 gene Intronic interruption of the transcription factor IIi,
pseudogene 1 (GTF2IP1)
Telomeric breakpoint (SNP nt position)
Last hemizygous probe locus 73772847 73900557
Homology block in medial LCR B B
Effect Intronic interruption of the GTF2I gene Intronic interruption of the GTF2IRD2 gene
a
LCR low copy repeat, nt nucleotide, SNP single-nucleotide polymorphism.
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criteria for autistic disorder [34-39], making the first
explanation plausible. However, we reported recently
on nine French individuals with autistic disorder associ-
ated with WBS, suggesting that comorbid autism and
WBS is more frequent than expected [40]. Furthermore,
some studies [38,41] have reported social communication
deficits in individuals with common WBSCR deletions,
suggesting that impairment in social communication
might be associated with WBS more frequently than
expected and tending to favor the alternate expression
explanation. Thus, verbal language in individuals with
WBS appears not to be socially adapted and relevant to
social communication. Our findings, in line with these
studies, suggest that abnormal social communication in
WBS patients forms a continuum ranging from classic
excessive talkativeness and overfriendliness to absence
of verbal language and poor social relationships.
Taking into account that both patients had common
WBSCR deletions, such a large variation in the behav-
ioral expression of the WBSCR deletion is not easily
explained. One explanation could rely on the intrinsic
variability in phenotypic expression in the theoretical con-
text of a polygenic, multifactorial model. A second pos-
sible model is a trans-acting effect, that is, a mutation or
polymorphism in one of the genes present in the retained
WBSCR. In this regard, the genes of the GTF2 family of
transcription factors are good candidates for modifiers
of the WBS phenotype. Thus, several authors have sug-
gested that GTF2I hemizygosity could be a major cause
of intellectual disability in patients with WBS [7,42]. It
is noteworthy that this gene has been related to lan-
guage [4]. Alteration in the expression of genes flanking
the breakpoints by positional effect, mediated by a cis-
acting mechanism, is an attractive third hypothesis [43].
Differences in the precise breakpoints could modify ex-
pression of nonhemizygous flanking genes. Genes flanking
the deletion could have their expression altered by the
rearrangement and participate in the phenotype even if
they do not vary in copy number [44]. However, mo-
lecular characterization of the deletion in our two pa-
tients excludes the possibility of an atypical genomic
rearrangement.
The phenotypic variability observed in patients with
deletion of the WBSCR could also result from inter-
action with other genetic, environmental or stochastic
factors. One possible modifying or epistatic locus is the
5-HTTLPR allele of the serotonin transporter (5-HTT)
gene. Both patients were homozygous for the s allele.
Although 5-HTTLPR alleles have not been consistently
associated with autism per se, several studies have reported
that the s allele is associated with the most severe autis-
tic impairment in communication and social interaction
[45-47]. Thus, allelic transmission in autism probands
was dependent upon the severity of impairments in the
social and communication domains, with greater s allele
transmission in severely impaired individuals. This rela-
tionship between s alleles and the severity of autistic
impairment was also seen when ratings of social and
communication behaviors were compared across ss, ls
and ll genotypes [45]. These findings are consistent with
the suggestion that the ss genotype generally has deleteri-
ous effects on human and nonhuman behavior [48-50].
The observation that infants homozygous for the s allele
have lower orientation and alertness scores [51] may
also be relevant to an influence of the HTT gene on the
phenotypic spectrum of WBS. In addition, the reported
association of the HTT promoter polymorphism with
anxiety-related traits in the general population [52] fur-
ther stimulates interest in HTT as a possible candidate
gene to modify the WBS behavioral phenotype. Given
that the frequency of the s allele in the general popula-
tion (in samples of predominately northern European
ancestry) is as high as 43% [52,53] (approximately 18%
homozygosity), one would expect to find a substantial
proportion of WBS patients with the ss genotype. The
probability that any two WBS patients would both have
the ss genotype is approximately 0.18 × 0.18, or 0.032.
The co-occurrence of WBS and autistic disorder might
be underestimated, given the nondetection of autistic
social communication impairments in individuals with
the typical WBSCR deletion [38,41]. This raises issues
related to fundamental difficulties in making the diag-
nosis of autistic disorder, especially when associated
with genetic disorders and intellectual disability [54,55].
In addition, the search for behaviors related to autism
spectrum disorders in patients with WBS may have
important clinical implications, considering that some
children with WBS could benefit from therapies offered to
children with autistic disorder. Similarly, the frequency
of WBS among children with autistic disorder might be
underestimated, considering that, based on our experi-
ence in France, practitioners working with children with
autistic disorder do not ask routinely for a clinical gen-
etic examination with a clinical morphological examination
to search for genetic disorders associated with autism,
including WBS. This situation highlights the need to
conduct systematically a clinical genetic examination to
search for underlying genetic disorders in all individuals
with an autistic behavioral phenotype.
The presence of frank hyperserotonemia and lower mela-
tonin production in patients 1 and 2 is intriguing. Previous
investigators who studied measurements of platelet sero-
tonin in two WBS patients with hyperserotonemia also
reported autistic behavior, including severe deficit in verbal
communication with typical autistic language impairments,
such as echolalia or repetitive and noncommunicative
vocalizations [34]. An absence of such behavior in WBS
patients with normal serotonin levels has been reported
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[56]. The hypothesis of a possible role of hyperserotonemia
in autistic behavior associated with WBS is strengthened by
the well-replicated high frequency of hyperserotonemia
in children with autistic disorder (25% to 50% according
to many studies, whereas the frequency of hyperserotonemia
in the general population is about 2.3%) [21]. It is note-
worthy that hyperserotonemia is a characteristic neuro-
chemical phenotype associated with autism, but is not
specific of this disorder (hyperserotonemia has been
observed, for example, in non-autistic individuals with
intellectual disability since the Schain and Freedman
first study in 1961 [57]). Hyperserotonemia might be
related less to the nosographic category of autism than
to a dimensional impairment, notably in the verbal com-
munication dimension. Thus, several studies have found
significant negative associations between hyperserotonemia
and verbal expressive abilities in individuals with autis-
tic disorder [58,59]. It can be speculated that hyper-
serotonemia and/or genetic variation contributing to
hyperserotonemia might influence the behavioral ex-
pression of the WBS phenotype, especially in the verbal
communication domain, with a possible total absence of
expressive language persisting even during adulthood.
In this regard, the role of the GTF2IRD1 gene might be
of interest considering that mice with disruption of
GTF2IRD1, used as a behavioral animal model of WBS,
showed enhanced prefrontal 5-HT1A-mediated inhibi-
tory responses following bath applications of 5-HT [60].
This finding might be relevant to the disinhibition ob-
served in individuals with WBS and their hyperensitivity
to serotonergic medicines such as the selective serotonin
reuptake inhibitors (SSRIs) [61]. Given bloodbrain barrier
considerations, it seems doubtful that peripheral platelet
hyperserotonemia could directly affect neurodevelopment.
However, given the critical early role of serotonin in embry-
onic and neuronal development and the presence of appar-
ent serotonergic abnormality (hyperserotonemia) in autistic
behavior associated with WBS, a role for serotonin is worth
considering. At the least, it can be suggested that platelet
serotonin levels might offer a potential predictor of an
autism behavioral phenotype in WBS. It might also be
of interest that epigenetic mechanisms involving gene X
environment interactions and effects on the serotonin-
ergic system [62] have been found in several genetic
syndromes associated with autism spectrum disorders
[63]. Further studies on gene X environment interactions,
including epigenetic mechanisms, are necessary to better
understand the association between common WBSCR
deletions and typical autistic behavioral and neuro-
chemical phenotypes.
Conclusions
In two individuals, we found the classical WBSCR dele-
tion to be associated with severe autism, including a
total absence of expressive language, which usually is not
reported for individuals with common WBS. Future re-
search is required to ascertain the mechanisms underlying
this association between WBS and severe autistic disorder
and to better understand the influence of genetic back-
ground and specific epistatic effects in WBS. The possible
role of serotonin-related genes and serotonergic abnor-
mality in the expression of social and communication
behaviors in WBS may be of particular interest. Further
studies are necessary to document the possible associ-
ation of hyperserotonemia and/or HTT alleles as modi-
fiers of the WBS neurocognitive profile in larger cohorts
of individuals with WBS, with or without autistic dis-
order. From this perspective, WBS provides a challenging
but relatively well-defined and potential fruitful model
to develop integrated genetic, cognitive, behavioral and
neurochemical approaches to study genotypephenotype
correlations as well as possible geneenvironment interac-
tions and genetic background effects.
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